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OBJECTIVES The aim of the present study was to assess the contribution of angiotensin-converting enzyme
(ACE) inhibitor therapy to bradykinin-induced tissue-type plasminogen activator (t-PA)
release in patients with heart failure (HF) secondary to ischemic heart disease.
BACKGROUND Bradykinin is a potent endothelial cell stimulant that causes vasodilatation and t-PA release.
In large-scale clinical trials, ACE inhibitor therapy prevents ischemic events.
METHODS Nine patients with symptomatic HF were evaluated on two occasions: during and following
seven-day withdrawal of long-term ACE inhibitor therapy. Forearm blood flow was
measured using bilateral venous occlusion plethysmography. Intrabrachial bradykinin (30 to
300 pmol/min), substance P (2 to 8 pmol/min), and sodium nitroprusside (1 to 4 pmol/min)
were infused, and venous blood samples were withdrawn from both forearms for estimation
of fibrinolytic variables.
RESULTS On both study days, bradykinin and substance P caused dose-dependent vasodilatation and
release of t-PA from the infused forearm (p  0.05 by analysis of variance [ANOVA]).
Long-term ACE inhibitor therapy caused an increase in forearm vasodilatation (p  0.05 by
ANOVA) and t-PA release (p  0.001 by ANOVA) during bradykinin, but not substance
P, infusion. Maximal local plasma t-PA activity concentrations approached 100 IU/ml, and
maximal forearm protein release was 4.5 g/min.
CONCLUSIONS Long-term ACE inhibitor therapy augments bradykinin-induced peripheral vasodilatation
and local t-PA release in patients with HF due to ischemic heart disease. Local plasma t-PA
activity concentrations approached those seen during systemic thrombolytic therapy for acute
myocardial infarction. This may contribute to the primary mechanism of the anti-ischemic
effects associated with long-term ACE inhibitor therapy. (J Am Coll Cardiol 2002;40:
961–6) © 2002 by the American College of Cardiology Foundation
Bradykinin is a potent endothelium-dependent vasodilator
that has a brief duration of action due to its rapid degrada-
tion by angiotensin-converting enzyme (ACE). In addition
to acting as an inflammatory mediator, bradykinin is closely
involved in fibrinolytic and coagulation cascades. During the
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contact phase of blood coagulation, it is released after cleavage
of high-molecular-weight kininogen by kallikrein (1). It is also
a potent stimulant for the release of tissue-type plasminogen
activator (t-PA) from the endothelium (2). Thus, when plaque
rupture or erosion activates the intrinsic coagulation pathway,
liberation of bradykinin may represent an important negative
feedback loop in which bradykinin-induced t-PA release in-
hibits intravascular thrombus formation.
Large-scale clinical trials of patients with heart failure
(HF) or ischemic heart disease indicate a reduction in
recurrent infarction rates with ACE inhibitor therapy (3).
The mechanisms underlying this anti-ischemic benefit may
relate, in part, to the effects on endogenous fibrinolysis.
Inhibition of ACE enhances bradykinin-induced vasodila-
tation and endothelial t-PA release in healthy volunteers
(2). However, to date, there has been no assessment of the
effect of long-term ACE inhibition on acute endogenous
t-PA release in patients with HF or ischemic heart disease.
Therefore, the aim of this study was to determine whether
long-term ACE inhibition potentiates acute t-PA release in
patients with HF secondary to ischemic heart disease.
METHODS
Patients. Nine patients with New York Heart Association
functional class II or III HF secondary to ischemic heart
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disease participated in the study, which was undertaken
with the approval of the local Research Ethics Committee,
in accordance with the Declaration of Helsinki, and each
subject gave written, informed consent. All subjects had
been maintained on a maximally tolerated dose of an ACE
inhibitor for more than six months, and they abstained from
alcohol for 24 h and from food and caffeine-containing
drinks for at least 4 h before each study.
Measurements. FOREARM BLOOD FLOW AND HEMODY-
NAMICS. Blood flow was measured in both forearms by
venous occlusion plethysmography using mercury-in-
Silastic strain gauges applied to the widest part of the
forearm, as previously described (2,4). Blood pressure and
heart rate were monitored in the noninfused arm at intervals
throughout each study by using a semi-automated nonin-
vasive oscillometric sphygmomanometer (Takeda UA 751,
Takeda Medical Inc., Tokyo, Japan).
ASSAYS. Venous cannulae (17-gauge) were inserted into
large subcutaneous veins of the antecubital fossa in both
arms. Ten to 20 ml of blood was withdrawn simultaneously
from each arm and collected into acidified buffered citrate
(Biopool Stabilyte, Umea˚, Sweden; for t-PA assays) and
citrate (Monovette, Sarstedt, Nu¨mbrecht, Germany; for
plasminogen activator inhibitor type 1 [PAI-1] assays) tubes
and kept on ice before being centrifuged at 2,000 g for 30
min at 4°C. Platelet-free plasma was decanted and stored at
80°C before assay. Plasma t-PA and PAI-1 antigen and
activity concentrations were determined using enzyme-
linked immunosorbent assays and a photometric method, as
previously described (2,4).
Study design. Patients were evaluated at 9 AM on two
occasions: during and after seven-day withdrawal of long-
term ACE inhibitor therapy. On the appropriate study day,
oral ACE inhibitor therapy was administered at 8 AM. The
brachial artery of the nondominant arm was cannulated with
a standard 27-gauge steel-wire needle (Cooper’s Needle
Works Ltd., Birmingham, UK) under local anesthesia. The
total rate of intra-arterial infusions was maintained constant
at 1 ml/min, and forearm blood flow was measured every 10
min throughout all studies. Intrabrachial infusions of sub-
stance P (Clinalfa AG, La¨ufelfingen, Switzerland) at 2, 4,
and 8 pmol/min, bradykinin (Clinalfa AG) at 30, 100, and
300 pmol/min, and sodium nitroprusside (David Bull Lab-
oratories, Warwick, UK) were given at 1, 2, and 4 g/min
for 10 min at each dose in a randomized order (2). Saline
was infused for 30 min before the substance P, sodium
nitroprusside, and bradykinin infusions.
Data analysis and statistics. Forearm blood flow was
calculated for individual venous occlusion cuff inflations, as
previously described (2,4). Estimated net release of t-PA
activity and antigen was previously defined as the product of
the infused forearm plasma flow (based on the mean
hematocrit and infused forearm blood flow) and the con-
centration difference between the infused and noninfused
arms (2,4). Data were examined, where appropriate, by
analysis of variance (ANOVA) with repeated measures and
the two-tailed paired Student t test, using Microsoft Excel
97. All results are expressed as the mean value  SEM.
Statistical significance was set at the 5% level.
RESULTS
Patient characteristics are shown in Table 1. After with-
drawal of ACE inhibitor therapy, baseline mean arterial
pressure appeared to rise, but this was not statistically
significant. There were no significant changes in heart rate,
blood pressure or noninfused forearm blood flow (Table 1,
Fig. 1) (data on file, University of Edinburgh) during or
between the study days.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
d.f.  degree of freedom
HF  heart failure
MI  myocardial infarction
PAI-1  plasminogen activator inhibitor type 1
t-PA  tissue-type plasminogen activator
Table 1. Patient characteristics (n  9)














Ejection fraction (%) 25  5
Shortening fraction (%) 10  2
LVEDD (mm) 64  2
Heart rate (beats/min)
Visit 1 61  5
Visit 2 61  4
Mean arterial pressure* (mm Hg)
Visit 1 84  4
Visit 2 89  5
Forearm blood flow (ml/100 ml/min)
Visit 1
Noninfused 2.3  0.2
Infused 2.3  0.2
Visit 2
Noninfused 2.8  0.6
Infused 2.6  0.3
Data are presented as the number of patients or mean value  SEM. *Diastolic
pressure  one-third of pulse pressure.
ACE  angiotensin-converting enzyme; LVEDD  left ventricular end-diastolic
diameter; Visit 1  during long-term ACE inhibition; Visit 2  after seven-day
withdrawal of long-term ACE inhibition.
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Forearm blood flow responses. Sodium nitroprusside
(data on file), substance P, and bradykinin caused dose-
dependent forearm vasodilatation during each study visit
(ANOVA for blood flow response, p  0.001 for all; n  9
at baseline and with the three doses, degree of freedom
(d.f.)  3) (Fig. 1). In the presence of long-term ACE
inhibition, forearm vasodilatation was augmented during
bradykinin (ANOVA for ACE inhibition vs. no ACE
inhibition, p  0.05; n  9 for blood flow at baseline and
with the three doses, d.f.  1), but not substance P or
sodium nitroprusside (p  NS) infusion.
Plasma fibrinolytic variables. Bradykinin and substance P
caused dose-dependent increases in plasma t-PA antigen
and activity concentrations in the infused arm (ANOVA for
plasma t-PA concentrations, p  0.05 for all; n  9 at
baseline and with the three doses, d.f.  3) (Fig. 1). Plasma
t-PA antigen and activity concentrations were significantly
augmented during bradykinin (ANOVA for ACE inhibi-
tion vs. no ACE inhibition, p  0.001; n  9 for plasma
t-PA concentrations at baseline and with the three doses,
d.f.  1), but not substance P (p  NS) infusion in the
presence of long-term ACE inhibition.
Basal plasma PAI-1 antigen concentrations were lower in
the presence (38  6 ng/ml) than in the absence (48  7
ng/ml) of ACE inhibitor therapy (paired t test for ACE
inhibition vs. no ACE inhibition, p  0.02; n  9 for
plasma PAI-1 concentrations, d.f.  1). Bradykinin and
substance P administration had no effect on plasma PAI-1
concentrations (data on file, University of Edinburgh).
Release of t-PA. Substance P and bradykinin caused dose-
dependent increases in the plasma t-PA antigen and activity
concentration differences between the forearms, as well as
the estimated net release of t-PA antigen and activity during
each study visit (ANOVA for t-PA release, p 0.01 for all;
n  9 for t-PA release or concentration difference at
baseline and with the three doses, d.f.  3) (Fig. 2). During
ACE inhibition, there was a massive increase in
bradykinin-induced (ANOVA for ACE inhibition vs. no
ACE inhibition, p  0.001; n  9 for t-PA release at
baseline and with the three doses, d.f.  1) (Fig. 2), but
not substance P–induced (p  NS), release of t-PA
antigen and activity (increases in the area under the curve
of 520% and 877%, respectively). Post-hoc analysis iden-
tified no significant effect of other concomitant medica-
Figure 1. Effect of intra-arterial bradykinin and substance P infusions on blood flow and plasma tissue-type plasminogen activator (t-PA) antigen (solid
lines) and activity (dashed lines) concentrations in the infused (solid symbols) and noninfused (open symbols) arms in the presence (left) or absence (right)
of angiotensin-converting enzyme (ACE) inhibition. *p  0.05 by analysis of variance (ANOVA). †p  0.001 by ANOVA for long-term ACE inhibition
versus no ACE inhibition.
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tions on substance P–induced or bradykinin-induced
t-PA release.
DISCUSSION
For the first time, to the best of our knowledge, we have
shown that in patients with HF secondary to ischemic heart
disease, long-term ACE inhibition markedly potentiates
bradykinin-induced endogenous t-PA release from the en-
dothelium. However, this potentiation appears to be specific
to bradykinin, because ACE inhibition did not influence
substance P–induced t-PA release. These findings suggest
that the beneficial clinical and vascular effects of ACE
inhibition may be partly mediated through the acute local
augmentation of bradykinin-induced t-PA release.
Magnitude of t-PA release. Long-term ACE inhibition
produced a massive augmentation of bradykinin-induced
t-PA release across the forearm vascular bed. The approx-
imate fivefold increase in t-PA antigen release and the
20% reduction in plasma PAI-1 antigen concentrations
led to the approximate ninefold increase in the release of
active t-PA. Our group has previously shown that
bradykinin-induced t-PA release is augmented by ACE
inhibition in healthy volunteers, but this was modest at
approximately twofold only (2). The dramatic potentiation
of active t-PA release in the present study is exemplified by
the observation that the maximal local forearm concentra-
tions of active t-PA (99 IU/ml at 300 pmol/min of
bradykinin) approached those observed during systemic
thrombolysis during acute myocardial infarction (MI) (100
to 1,000 IU/ml) (5). Moreover, it also underscores the large
capacity of the endothelium to release t-PA quickly—up to
4.5 g or 16,000 IU/min from the infused forearm at 300
pmol/min of bradykinin. Indeed, using intrabrachial sub-
stance P infusions, we have previously demonstrated sub-
stantial and sustained release of t-PA for up to 2 h (6).
Minai et al. (7) have recently reported that ACE inhibi-
tion produces an approximate twofold increase in
bradykinin-induced t-PA release in the coronary circulation
of patients with atypical chest pain and angiographically
normal coronary arteries. This is consistent with our previ-
ous findings in the peripheral circulation of healthy volun-
teers (2) and suggests that comparable endothelial fibrino-
lytic effects exist between the peripheral and coronary
circulations (8). The present study extends these previous
findings, because we have demonstrated a more marked
Figure 2. Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid lines) and activity (dashed lines) during bradykinin (right) and
substance P (left) infusions in the presence (solid circles) or absence (open circles) of angiotensin-converting enzyme (ACE) inhibition. p  0.01 by
analysis of variance (ANOVA) for all responses. *p  0.001 by ANOVA for long-term ACE inhibition versus no ACE inhibition.
964 Witherow et al. JACC Vol. 40, No. 5, 2002
Bradykinin, Fibrinolysis, and Long-Term ACE Inhibition September 4, 2002:961–6
augmentation of peripheral t-PA release in patients with
HF secondary to ischemic heart disease.
Mechanism of bradykinin-induced t-PA release. In
keeping with our previous work (2) and that by others (9),
ACE inhibition augmented the vasodilatation induced by
bradykinin but did not affect the vasodilatation or t-PA
release produced by substance P. This suggests that the
effect of ACE inhibition does not appear to reflect a
generalized enhancement of vascular function but is specific
to bradykinin. Brown et al. (10) and Gainer et al. (11) have
previously investigated the mechanism of bradykinin-
induced t-PA release in the human forearm. Bradykinin
induces t-PA release through a B2 receptor-dependent,
nitric oxide synthase-independent, and cyclooxygenase-
independent pathway (10). Brown et al. (10) have suggested
that bradykinin-induced t-PA release may be caused by an
endothelium-derived hyperpolarizing factor, although other
mediators may be involved. This group has also described a
potential interaction between the vascular responses to
bradykinin and the ACE gene insertion/deletion polymor-
phism (11). We have not explored this interaction because
of the small sample size of our study, but this may markedly
influence the fibrinolytic response to long-term ACE inhi-
bition in patients with HF or vascular disease, and it
requires further investigation.
Inflammation plays an important role in the pathogenesis
of HF (12), with elevated plasma concentrations of circu-
lating cytokines such as tumor necrosis factor-alpha (13).
Bradykinin receptor expression is altered by ACE inhibition
(14,15), inflammation (16), and chronic HF (14,15,17) and
may partly explain the proportionately greater and massive
release of t-PA from the endothelium.
Endothelial function, endogenous fibrinolysis, and
HF. The endothelium plays a vital role in the control of
blood flow, hemostasis, fibrinolysis, and inflammation.
Consequently, the maintenance and regulation of tissue
perfusion critically depends on the integrity of endothelial
function and the release of potent endothelium-derived
factors. After the seminal work of Furchgott and Zawadski
(18), it has been widely recognized that an array of media-
tors can influence vascular tone through endothelium-
dependent actions, and there is now extensive evidence of
abnormal endothelium-dependent vasomotion that is re-
versed by ACE inhibition in patients with HF (19,20).
However, although endothelium-dependent vasomotion is
important, it may not be representative of other aspects of
endothelial function, such as the regulation of endogenous
fibrinolysis.
Tissue plasminogen activator is a serine protease that
regulates the degradation of intravascular fibrin and is
released from the endothelium through the translocation of
a dynamic intracellular storage pool. If endogenous fibrino-
lysis is to be effective, then the rapid mobilization of t-PA
from the endothelium is essential, because thrombus disso-
lution is much more effective if t-PA is incorporated during,
rather than after, thrombus formation (21). This dynamic
aspect of endothelial function and fibrinolytic balance may
be directly relevant to the pathogenesis of atherothrombosis
and is not necessarily reflected by the basal plasma concen-
trations of t-PA (22–24).
Clinical relevance. The endogenous fibrinolytic system
can have important clinical effects, as exemplified by the
observation that in one-third of patients with an acute MI,
the infarct-related artery spontaneously reperfuses within
12 h (25–27). Moreover, low fibrinolytic activity is associ-
ated with an increased risk of MI in young men (28) and
predicts which patients with unstable angina will develop
MI (29). Clinical studies of patients with unstable angina
have also indicated that there is an enhanced activation of
the kallikrein system and that bradykinin release is increased
(30). Given this augmentation of bradykinin generation and
activation of the intrinsic coagulation pathway in acute
coronary syndromes, ACE inhibition may have major ben-
eficial effects on the acute local fibrinolytic balance by
markedly enhancing bradykinin-induced t-PA release in
areas of intravascular thrombus formation. This is consistent
with the observation that ACE inhibition improves the basal
fibrinolytic balance (31,32) and reduces myocardial troponin
release in patients with acute coronary syndromes (33).
Conclusions. Long-term ACE inhibitor therapy augments
bradykinin-induced peripheral vasodilatation and local
t-PA release in patients with HF due to ischemic heart
disease. Local plasma t-PA activity concentrations ap-
proached those seen during systemic thrombolytic therapy
for acute MI. This may contribute to the primary mecha-
nism of the anti-ischemic effects associated with long-term
ACE inhibitor therapy.
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